COMMUNIQUÉS West-GlobeNewswire

ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30/05/2024
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination with pembrolizumab [...]
Humacyte to Present at the Jefferies Global Healthcare Conference
30/05/2024
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]
New study identifies higher risk of depression and anxiety among young men, gay or bisexual, and racialized Canadian men
30/05/2024
43% of young men aged 19-29 are at risk of depression Moderate-to-high anxiety impacts 57% of young men, 45% of gay or bisexual men, and 42% of racialized men National study from the Canadian Men’s Health Foundation [...]
ORYZON to Provide Corporate Progress Updates at Several Events in June
30/05/2024
BIO International Convention 2024 European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
30/05/2024
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide [...]
Rezolute to Participate in the Jefferies Global Healthcare Conference
30/05/2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for [...]
Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
30/05/2024
Co-developing immune-evasive allogeneic TCR-iPS-T-cell therapies for the treatment of solid tumors SÖDERTÄLJE, Sweden and SAN FRANCISCO and KYOTO, Japan, May 30, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T- [...]
Enterome to Participate in the Jefferies Global Healthcare Conference
30/05/2024
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry [...]
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
30/05/2024
PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have [...]
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
30/05/2024
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early onset can be expected thanks to early [...]
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
30/05/2024
L’étude clinique réalisée en 2022 est maintenant publiée dans la revue à comité de lecture Neurology and Therapy Plus de details sur la bioéquivalence démontrée par rapport au médicament européen Dormicum® Efficacité [...]
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of [...]
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024
Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., [...]
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
30/05/2024
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation [...]
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
30/05/2024
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu les premières doses [...]
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
30/05/2024
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI ® (INN: Piflufolastat ( 18 F) also [...]
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
30/05/2024
A clinical study, published in the journal Food Science and Nutrition, showed that GBL-Memory 1 , a unique combination of L-theanine and Fructooligosaccharides, can improve memory by up to 10.1% GBL-Memory 1 is the [...]
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30/05/2024
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a [...]
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
30/05/2024
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May 30, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today [...]

Pages